摘要
目的:观察免疫治疗联合安罗替尼治疗难治性晚期非小细胞肺癌的疗效及不良反应。方法:回顾性分析我科接受免疫治疗联合安罗替尼治疗的9例经多周期化疗无效的难治性晚期非小细胞肺癌患者,包括肺鳞癌3例,肺腺癌6例,所有患者均为二线或三线化疗后治疗无效的病例。据实体瘤疗效评价标准(RECIST)1.1版进行近期疗效评价,并详细记录治疗相关不良反应。结果:1例患者为五线治疗,3例患者为四线治疗,5例患者为三线治疗。部分缓解3例,疾病稳定3例;疾病控制率为66.7%。最常见的药物不良反应包括疲劳(8例)、高血压(4例)、厌食(2例)、手足综合征(2例),均在2级以内,未出现4/5级药物不良反应。结论:免疫治疗联合安罗替尼对难治性晚期非小细胞肺癌疗效确切,不良反应可耐受。
OBJECTIVE To observe the efficacy and adverse reactions of immunotherapy combined with antrotinib in the treatment of refractory advanced non-small cell lung cancer.METHODS Retrospective analysis of 9 patients with refractory advanced non-small cell lung cancer who received immunotherapy combined with anrotinib in our department.Including 3 cases of lung squamous cell carcinoma and 6 cases of lung adenocarcinoma,solid tumor efficacy evaluation standard(RECIST)version 1.1.The treatment-related adverse reactions were recorded in detail.RESULTS One patient received fifth-line treatment,three patients received fourth-line treatment,and five patients received third-line treatment.There were 3 cases of partial remission and 3 cases of stable disease;the disease control rate was 66.7%.CONCLUSION Immunotherapy combined with anlotinib has a definite effect on refractory advanced non-small cell lung cancer,and adverse reactions can be tolerated.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2020年第S01期71-72,共2页
Chinese Journal of Cancer Prevention and Treatment
基金
解放军总医院第六医学中心创新培育基金(CXPY201916)
作者简介
第一作者:赵儒钢,男,浙江浦江人,主治医师,主要从事肿瘤放疗及靶向治疗的研究工作;通讯作者:赵向飞,男,山东蒙阴人,副主任医师,主要从事肿瘤综合治疗的研究工作,E-mail:article1977@163.com
